Introduction
Vildagliptin is (S)-1-[N-(3-hydroxy-1-adamantyl)glycyl] pyrrolidine-2-carbonitrile ( Fig.1) . Vildagliptinis a relatively new anti-diabetic drug used for controlling patient with type 2 diabetes mellitus. It is related to dipeptidyl peptidase-4 inhibitor drugs. Vildagliptinis are used either alone or in combination with other drugs such as metformin (MET), sulfonylurea or thiazolidinedione for better controlling of resistant patients. Combination of Vildagliptin and MET provides a superior HbA1c-lowering effect with a comparable overall tolerability profile and low risk of hypoglycemia [1] and [2] . Several methods have been reported for determination of Vildagliptin either alone or in combination with other drugs .The methods include spectrophotometric and spectrofluorometric methods [3] [4] [5] [6] , HPLC methods [7] [8] [9] [10] [11] [12] ,UPLC method [13] and HPTLC method [14] .
Pioglitazone hydrochloride is (±)-5-(p-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl)-2,4-thiazolidinedione hydrochloride (Fig.2) . Pioglitazone is one of thiazolidinediones group which is a class of oral anti-diabetic drugs that enhance target tissue insulin sensitivity. Pioglitazone has been shown to affect abnormal glucose and lipid metabolism associated with insulin resistance by enhancing insulin action on peripheral tissues [15] .The literature review showed many methods for estimation of Pioglitazone hydrochloride which include the official method according to USP 36 [16] and reported methods such as spectrophotometric methods [17] [18] [19] [20] [21] , HPLC methods [22] [23] [24] and HPTLC methods [25 and 26] .
Glimepirideis1-((p-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea (Fig.3) . Glimepiride is a sulfonylurea anti-diabetic drug with prolonged effect and moreover, it maintains a more physiological regulation of insulin secretion than Glibenclamide during physical exercise, suggesting that there may be less risk of hypoglycemia with Glimepiride. It acts by increasing the secretion of insulin by β-cells of the pancreas [15] .Glimepiride is officially reported in USP 36 [16] , and BP 2013 [27] . Several methods have been reported for determination of Glimepiride either alone or in combined dosage forms. The methods include spectrophotometric [28] [29] [30] [31] [32] [33] [34] [35] , HPLC [22] [23] [24] and [36] [37] and HPTLC [38, 39] . then diluted to the mark with the mobile phase. The solutions were filtered through 0.45 µm nylon membrane filter discs [Millipore TM , Milford, MA] before use. Further dilution was carried out using the mobile phase to suit the concentration domain covered by the calibration graphs. The solutions were chromatographed using the HPLC conditions described above and the concentrations of Vildagliptin, Pioglitazone and Glimepiride were calculated.
III.
Results And Discussion
HPLC method development and optimization
A new reliable, sensitive and accurate RP-HPLC method is developed for simultaneous determination of Vildagliptin, Pioglitazone and Glimepiride in bulk and the method is applied successfully to the pharmaceutical preparations containing these compounds. This is the first time to separate these three drugs. The chromatographic parameters such as detection wavelength, mobile phase composition, pH value and the flow rate were studied and optimized in order to provide an excellent assessment performance.
The UV absorption spectra of Vildagliptin, Pioglitazone, and Glimepiride prepared in the mobile phase were found to be in a region of 200-300 nm as represented in (Fig.4) . It is obvious that each drug does strongly contribute to the overall absorption spectrum of the mixture, resulting in an extensive overlapping between the drugs absorption spectra. Thus, introducing an HPLC technique for the simultaneous analysis of Vildagliptin, Pioglitazone and Glimepiride in ternary mixtures will be more favored than applying any conventional (direct) first derivative or derivative ratio spectrophotometric methods.
The effect of pH value of the buffer and percentage of organic modifier
One of our crucial interests during the method development was the choice of suitable mobile phase components with suitable pH value for better separation of the investigated drugs without affecting their chemical entity. It was noticed that acidic pH values are preferred with Pioglitazone and Glimepiride during their own analyses. However, an analysis at pH value above 7 was to be avoided because it could damage the reversed silica-based analytical columns C18, when they are used frequently. By using pH value of 3.5a good baseline separation was achieved during the experimental study for Vildagliptin, Pioglitazone, and Glimepiride After several preliminary investigatory chromatographic runs, it was concluded that phosphate buffers gave better peak symmetry than their acetate and citrate counterparts. It was also noticed that peak shapes were improved with increasing the buffer ionic strength with a non-significant change beyond 0.05 M. In order to avoid salt precipitation that can affect the lifespan of the used analytical column. A 0.05 M phosphate buffer was chosen for method validation. An initial mixture of methanol and phosphate buffer was tried in the ratio of (40:60, v/v). Unfortunately, Vildagliptin peak was observed to be forked and showed tailing this together with a delayed elution for Pioglitazone and Glimepiride that reached a (t R )> 8 min and > 20 min, respectively. When methanol was replaced with acetonitrile at the same ratio a better separation was obtained but with relative tailing and forking for Vildagliptin peak. Increasing the acetonitrile concentration to more than 40 % provided a more symmetrical Vildagliptin peak. Therefore, methanol was excluded again in the dilution process to remove the forking from Vildagliptin peak, a satisfactory separation of the three drugs Vildagliptin, Pioglitazone and Glimepiride was achieved using a mobile phase consisting of acetonitrile and 0.05 M potassium dihydrogen phosphate buffer, pH = 3.5, in a final ratio of (45: 55, v/v).
The effect of flow rate and wavelength -detection
In regard to the flow rate optimization; it was initially set at 1ml/min, causing Glimepiride to be eluted too late at > 18 min. Therefore, the flow rate was gradually increased until it was finally adjusted at 1.5 ml/min to separate Glimepiride at a reasonable time of 8.8 min. This modification allows completing the process of separation of Vildagliptin, Pioglitazone and Glimepiride within ten minutes with better resolution.
Lastly, the wavelength of detection was set regarding the drugs UV absorption spectra and their relative concentrations within the pharmaceutical formulations. Where, 50:30:4 the ratio of Vildagliptin, Pioglitazone and Glimepiride respectively in the dosage form. This is why; an optimum detection wavelength was set at 200 nm during the chromatographic separation, favoring the separation and quantification of Vildagliptin and the quantification of Glimepiride, which represent the less concentrated component of this ternary mixture, achieving adequate signal strengths for the three analytes in respect to each other. In addition, such chosen detection wavelength greatly improves the sensitivity of the proposed method towards the Vildagliptin, since the later possess a high molar absorptive coefficient at 200 nm.
The specificity of this HPLC method is illustrated at the typical chromatograms ( 
IV. Method Validation

Linearity and range (calibration curve)
The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are either, directly or through mathematical transformation proportional to the concentration of the analyte. This proposed HPLC method was assessed by least-squares linear regression analysis of the calibration curve [40] . According to the ICH guidelines [41] , at least five concentrations must be used. In this presented study, five different concentrations, of each studied drug were chosen and prepared as previously discussed. Each concentration was injected in triplicate and the mean value of the peak areas was imputed into a Microsoft Excel ® spreadsheet program for the calibration curve plotting. The repeated runs were genuine repeats and not just repetitions at the same reading in which three replicate samples of each concentration level were prepared; this in order to provide information on the variation of the peak area between samples of the same concentration. The regression analyses revealed satisfactory correlations (r = 0.9996 -0.9997), this, indicating a good linearity of the calibration graphs (Fig.5, 6&7 ).Characteristic parameters for the regression equations of the HPLC method obtained by least-squares treatment of results were given in table (1).
Precision
The precision of the proposed HPLC analysis was evaluated as repeatability and reproducibility levels; using three independent concentrations of each drug. The repeatability (intra-day precision) studies were performed on the same day, whereas, that of the intermediate precision (inter-day precision) were checked by repeating these studies on three consecutive days. Every sample was injected in triplicates and both the retention times (t R ) and peak areas were determined. Within the examined time range, the peak area results presented in table (2) and show excellent precision for the method both during one analytical run and between different runs, with an intra-day and inter-day R.S.D. (%), the range was 0.202-1.305 and 0.262-1.327, respectively.
Detection and quantitation limits
The limit of detection (LOD) for an HPLC method is the lowest drug concentration that produces a response detectable above the noise level of the system, typically taken as three times. The limit of quantification (LOQ) is the lowest level of the drug that can be accurately measured, and it is often evaluated as ten times the noise level. Both quantities were evaluated regarding the International Conference on Harmonization (ICH) guidelines [41] . Both the values of LOD and LOQ were assessed practically and given in table (1).
Accuracy
The accuracy of the proposed method, which is defined as the closeness or the nearness of the true and found values, was evaluated by measuring the drug recoveries by using the standard addition technique. The standard addition analysis involves the addition of three concentration levels of each drug standard solution (covering the linearity range and higher than LOQ) to pre-analyzed pharmaceutical samples containing; 25, 15 and 2 µg mL −1 of Vildagliptin, Pioglitazone and Glimepiride respectively. Each set of addition was repeated five times, and the results obtained were compared with those expected from the calibration curve, table (3).
Selectivity
The selectivity of the proposed method was checked by preparing five laboratory-prepared mixtures of the studied drugs at various concentrations within their linearity range. The laboratory-prepared mixtures were analyzed according to the previous procedure described under the proposed method. Satisfactory results were obtained as listed in table (4) indicating the high selectivity of the proposed method for simultaneous determination of the studied drugs.
Robustness
Robustness relates to the capacity of the method to remain unaffected by small but deliberate variations introduced into the method critical parameters. For this, four chromatographic parameters such as; buffer pH, organic composition of the mobile phase, elution flow rate and the detection wavelength were varied around the value set in the proposed method in order to reflect changes likely to arise in different testing environments. The pH was varied in the range 3.4-3.6 (± 0.1 units), while as the mobile phase organic strength was varied through ± 1 % (v/v) alteration of the acetonitrile compositing proportions along the chromatographic separation. On the other hand, the influence of the flow rate was evaluated between 1.45-1.55 ml/min, while as the detection wavelength was evaluated over ± 2 nm alterations. During the robustness study, only one factor was changed at a time and the analyses were performed in replicate injections (n = 3). The results, presented in table (5), confirm the method robustness since the observed variations were less than 1.401 %.
System suitability test
System suitability tests (SST) are based on the concept that the equipment, electronics, analytical operations and samples to be analyzed constitute an integral system that can be evaluated as such. These tests were performed in accordance with the BP guidelines to ensure adequate performance of both the chromatographic system and the equipment, for the analysis to be performed. The repeatability test was carried out by injecting six separated injections at concentrations 50, 30, and 4 µg/ml regarding VILD, Pioglitazone, Other chromatographic parameters were calculated from experimental data, such as; capacity factor (k') also known as mass distribution ratio (D m ), tailing factor (T f ) also known as peak asymmetry factor (A s ) and the apparent number of theoretical plates (N). All of these parameters are usually employed in assessing the performance of the column. Results obtained from system suitability tests are presented in table (6) . Good agreement was found when results were compared with recommended values.
Analytical solutions stability
The solutions were stored in tightly capped volumetric flasks and wrapped with aluminum foil under reduced light conditions. It was found that Vildagliptin and Pioglitazone analytical solutions exhibited no changes for at least 10 days when stored refrigerated at 4˚C and for 24 hours when kept at room temperature. Glimepiride analytical solution in methanol exhibited no changes for 7 days when stored refrigerated at 4˚C and for 18 hours when kept at room temperature. Solutions of the studied compounds in the mobile phase exhibited no changes for 8 hours when kept at room temperature.
Analysis of pharmaceutical products
The validated HPLC method was applied for the determination of Vildagliptin, Pioglitazone and Glimepiride in pharmaceutical preparation using Gliptus ® and Amaglust ® tablets (Fig. 9) . Three replicate determinations were performed at each concentration level. Satisfactory results were obtained for each compound in good agreement with label claims table (7) . The obtained results were compared statistically by Student's t-test (for accuracy) and variance ratio F-test (for repeatability) with the reported method [7] for Vildagliptin & [42] for Pioglitazone and Glimepiride. The results showed that the calculated t and F values were smaller than the critical values at 95% confidence limit indicating that there is no significant difference between the proposed and reported methods, table (7).
V. Conclusion
The proposed HPLC method provides simple, accurate and reproducible quantitative analysis for the simultaneous determination of pharmaceutical products containing Vildagliptin, Pioglitazone, and Glimepiride without any interference from excipients. The study showed that this chromatographic method is suitable for routine analysis of the studied compounds in their pharmaceutical preparations; the proposed RP-HPLC method is the first study for the simultaneous determination of Vildagliptin, Pioglitazone and Glimepiride as multi-drug pharmaceutical formulations providing a collective chromatographic profile regarding these three drugs. This, in turn, will be suitable as a guideline for the routine and QC analyses. 
